BioVersys AG (SWX:BIOV)

Switzerland flag Switzerland · Delayed Price · Currency is CHF
28.50
-0.40 (-1.38%)
At close: Sep 26, 2025
-1.38%
Market Cap178.24M
Revenue (ttm)1.31M
Net Income (ttm)-19.36M
Shares Out5.84M
EPS (ttm)-4.34
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume60
Average Volume7,769
Open28.50
Previous Close28.90
Day's Range28.50 - 28.50
52-Week Range24.40 - 37.00
Betan/a
RSI42.86
Earnings DateSep 10, 2025

About BioVersys AG

BioVersys AG, a clinical stage biopharmaceutical company, focuses on identification, development, and commercialization of novel antibacterial products for serious life-threatening infections caused by multi-drug-resistant bacteria. It develops BV100 that is in Phase 3 clinical trial for carbapenem resistant Acinetobacter baumannii lung and blood stream infections; and in Phase 1 trial in patients with hepatic impairment and a bronchoalveolar lavage (BAL). The company is also developing Alpibectir that is in Phase 2a clinical trial for the trea... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2008
Employees 27
Stock Exchange SIX Swiss Exchange
Ticker Symbol BIOV
Full Company Profile

Financial Performance

Financial Statements

News

There is no news available yet.